Cargando…

Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer

INTRODUCTION: The aim of this study was to explore if the preoperative neutrophil–lymphocyte ratio (NLR) and fibrinogen level can help in distinguishing between muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). METHODS: We identified 669 patients who underwent sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Chengquan, Lu, Bingxin, Diao, Chengwen, Zhao, Kun, Wang, Xinpeng, Ma, Baojing, Lu, Baojian, Sun, Erlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982501/
https://www.ncbi.nlm.nih.gov/pubmed/27540305
http://dx.doi.org/10.2147/OTT.S107445
_version_ 1782447791092531200
author Ma, Chengquan
Lu, Bingxin
Diao, Chengwen
Zhao, Kun
Wang, Xinpeng
Ma, Baojing
Lu, Baojian
Sun, Erlin
author_facet Ma, Chengquan
Lu, Bingxin
Diao, Chengwen
Zhao, Kun
Wang, Xinpeng
Ma, Baojing
Lu, Baojian
Sun, Erlin
author_sort Ma, Chengquan
collection PubMed
description INTRODUCTION: The aim of this study was to explore if the preoperative neutrophil–lymphocyte ratio (NLR) and fibrinogen level can help in distinguishing between muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). METHODS: We identified 669 patients who underwent surgery at our institution, and evaluated their preoperative NLRs and fibrinogen levels. Patients were divided into two groups, NMIBC (group-I) and MIBC (group-II), according to the postoperative pathology. For the intergroup comparison, data obtained from the two groups were evaluated using independent samples t-test. The cutoff value of the NLR, fibrinogen level, and integrated NLR and fibrinogen level was determined with receiver operating characteristic (ROC) curve. RESULTS: The mean NLRs of group-I and group-II were found as 2.71±2.46 and 4.66±8.00, respectively (P<0.001). The fibrinogen levels of the two groups were ~3.13±0.70 g/L and 3.41±0.84 g/L, respectively (P=0.001). Whether the NLR, fibrinogen level, and integrated NLR and fibrinogen level can help in distinguishing between MIBC and NMIBC was evaluated with ROC curve. The cutoff value of NLR was estimated as 2.01 according to the Youden index. With this value, sensitivity was found as 67.1%, specificity was 52.7%, and area under receiver operating characteristic (ROC) curve (AUC) was 0.601 (P=0.031). The cutoff value of fibrinogen level was estimated as 3.17 g/L according to the Youden index. Accordingly, sensitivity was found as 58%, specificity was 58%, and AUC was 0.60 (P=0.001). The cutoff value of integrated NLR and fibrinogen level was found as 0.166; the sensitivity was found as 86%, specificity was 42%, and AUC was 0.801 (P=0.01). CONCLUSION: The data obtained in this study suggested that 67.1% of Ta-T1 tumors were likely to be invasive if the NLR was >2.01 and 58% were likely to be invasive if the fibrinogen level was >3.17 g/L. When we used both the NLR and fibrinogen level to distinguish between the MIBC and NMIBC, sensitivity was found to be 86%, and specificity was 42%.
format Online
Article
Text
id pubmed-4982501
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49825012016-08-18 Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer Ma, Chengquan Lu, Bingxin Diao, Chengwen Zhao, Kun Wang, Xinpeng Ma, Baojing Lu, Baojian Sun, Erlin Onco Targets Ther Original Research INTRODUCTION: The aim of this study was to explore if the preoperative neutrophil–lymphocyte ratio (NLR) and fibrinogen level can help in distinguishing between muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC). METHODS: We identified 669 patients who underwent surgery at our institution, and evaluated their preoperative NLRs and fibrinogen levels. Patients were divided into two groups, NMIBC (group-I) and MIBC (group-II), according to the postoperative pathology. For the intergroup comparison, data obtained from the two groups were evaluated using independent samples t-test. The cutoff value of the NLR, fibrinogen level, and integrated NLR and fibrinogen level was determined with receiver operating characteristic (ROC) curve. RESULTS: The mean NLRs of group-I and group-II were found as 2.71±2.46 and 4.66±8.00, respectively (P<0.001). The fibrinogen levels of the two groups were ~3.13±0.70 g/L and 3.41±0.84 g/L, respectively (P=0.001). Whether the NLR, fibrinogen level, and integrated NLR and fibrinogen level can help in distinguishing between MIBC and NMIBC was evaluated with ROC curve. The cutoff value of NLR was estimated as 2.01 according to the Youden index. With this value, sensitivity was found as 67.1%, specificity was 52.7%, and area under receiver operating characteristic (ROC) curve (AUC) was 0.601 (P=0.031). The cutoff value of fibrinogen level was estimated as 3.17 g/L according to the Youden index. Accordingly, sensitivity was found as 58%, specificity was 58%, and AUC was 0.60 (P=0.001). The cutoff value of integrated NLR and fibrinogen level was found as 0.166; the sensitivity was found as 86%, specificity was 42%, and AUC was 0.801 (P=0.01). CONCLUSION: The data obtained in this study suggested that 67.1% of Ta-T1 tumors were likely to be invasive if the NLR was >2.01 and 58% were likely to be invasive if the fibrinogen level was >3.17 g/L. When we used both the NLR and fibrinogen level to distinguish between the MIBC and NMIBC, sensitivity was found to be 86%, and specificity was 42%. Dove Medical Press 2016-08-08 /pmc/articles/PMC4982501/ /pubmed/27540305 http://dx.doi.org/10.2147/OTT.S107445 Text en © 2016 Ma et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ma, Chengquan
Lu, Bingxin
Diao, Chengwen
Zhao, Kun
Wang, Xinpeng
Ma, Baojing
Lu, Baojian
Sun, Erlin
Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title_full Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title_fullStr Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title_full_unstemmed Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title_short Preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
title_sort preoperative neutrophil–lymphocyte ratio and fibrinogen level in patients distinguish between muscle-invasive bladder cancer and non-muscle-invasive bladder cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982501/
https://www.ncbi.nlm.nih.gov/pubmed/27540305
http://dx.doi.org/10.2147/OTT.S107445
work_keys_str_mv AT machengquan preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT lubingxin preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT diaochengwen preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT zhaokun preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT wangxinpeng preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT mabaojing preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT lubaojian preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer
AT sunerlin preoperativeneutrophillymphocyteratioandfibrinogenlevelinpatientsdistinguishbetweenmuscleinvasivebladdercancerandnonmuscleinvasivebladdercancer